— Research note —
AOD-9604
Modified C-terminal fragment of human growth hormone (residues 176-191) investigated for lipolytic activity decoupled from somatogenic effects.
AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the carboxy-terminal region of human growth hormone (residues 177-191) with an additional tyrosine residue at the N-terminus to enhance stability. The molecule was developed by Metabolic Pharmaceuticals (Monash University spinout) in the late 1990s on the basis of earlier observations by Ng and Bornstein that fragments of growth hormone retained lipolytic activity in adipocyte preparations without the growth-promoting or insulin-antagonizing actions of the full hormone.
The defining property of AOD-9604 in research models is its apparent dissociation of lipolytic from somatogenic effects. In murine and ovine adipocyte studies, the peptide has been observed to stimulate lipolysis and inhibit lipogenesis without engaging the growth hormone receptor in a manner that activates JAK2/STAT5 signaling. This profile attracted interest as a research probe for adipocyte metabolism and as a candidate molecule in obesity-related preclinical programs.
Clinical research conducted in the 2000s included phase 2 trials examining body composition endpoints in obese volunteers. Results were mixed: while early proof-of-concept studies suggested modest body-fat reductions, larger pivotal-style trials did not reach predefined efficacy thresholds, and the molecule did not advance to regulatory approval as a pharmaceutical. The compound subsequently received Generally Recognized as Safe (GRAS) self-affirmation as a food ingredient and has been examined in cartilage and osteoarthritis research models.
For laboratory researchers, AOD-9604 remains a useful pharmacological tool for probing the structure-activity relationships of growth hormone, particularly the question of whether discrete domains of the parent molecule carry distinct biological activities. The compound is supplied for research use only and is not intended for human consumption.
Mechanism
The precise mechanism of AOD-9604 remains incompletely characterized despite three decades of research interest. The peptide corresponds to a region of growth hormone not directly involved in canonical GHR engagement, and binding affinity to the somatogenic receptor is negligible in radioligand assays. Instead, the molecule has been proposed to act through a distinct, as-yet-undefined receptor or through allosteric modulation of beta-adrenergic signaling in adipocytes.
In rodent adipocyte preparations, AOD-9604 has been observed to elevate cAMP and stimulate hormone-sensitive lipase activity, increasing free fatty acid release. Reductions in fatty acid synthase expression and acetyl-CoA carboxylase activity have been reported in some studies, consistent with reduced de novo lipogenesis. Effects on chondrocyte metabolism, including upregulation of aggrecan and type II collagen synthesis, have been observed in cartilage explant models, generating interest in osteoarthritis research applications.
Research history
The research history of AOD-9604 traces to the 1970s and 1980s when Ng, Bornstein, and Frank Ng identified lipolytic activity in proteolytic fragments of growth hormone. The Monash University group led by Frank Ng and Roger Heffernan characterized the activity to the C-terminal region and developed AOD-9604 as an optimized synthetic analog in the late 1990s under the company Metabolic Pharmaceuticals.
Phase 1 and phase 2a studies conducted in the early 2000s reported tolerability and modest effects on lipid oxidation indices in obese research volunteers. A pivotal phase 2b study in 2007 enrolled approximately 500 participants and reported sub-threshold effects on body weight, leading to discontinuation of the obesity development program.
The molecule was subsequently licensed for nutraceutical applications and received self-affirmed GRAS status in 2014. Independent academic research has examined the peptide in cartilage repair and osteoarthritis models, with publications from groups including the University of Western Sydney reporting effects on chondrocyte anabolism. The compound continues to appear in research-chemical catalogs as a reference probe for structure-activity studies of growth hormone-derived peptides.
References
- Ng FM, Bornstein J. 1978. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol.
- Heffernan M, et al. 2001. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice. Endocrinology. PMID: 11606430
- Ng FM, et al. 2000. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res.
- Stier H, et al. 2013. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab.
- Kwon DR, Park GY. 2015. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. PMID: 26116595
Do you have any questions about AOD-9604?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.